About Us

Stempeutics Research Private Limited (Stempeutics) is a leading stem cell company developing stem cell based medicinal products, with facilities in Bangalore and Manipal (India) as well as in Kuala Lumpur (Malaysia). The company is in the process of bringing the first stem cell therapy product to the Indian market.

Stempeutics has completed pre clinical studies demonstrating the appropriate safety profile of human bone marrow-derived ex vivo cultured adult mesenchymal stem cells in allogenic settings.

Stempeutics obtained Drug Controller General of India (DCGI) approval for conducting multi centric phase I/II combined double blind randomized allogenic clinical trials (on-going) for its two most advanced programs, indicated in acute myocardial infarction (AMI) and critical limb ischemia (CLI). This is the FIRST allogenic stem cell clinical trial approved in India. A phase 3 study is planned to be conducted in India in 2012; another phase III study will be planned outside India. This second phase 3 is likely to be supportive for the registration of the product in ASEAN countries.

In addition, Stempeutics recently obtained DCGI approval for phase II Clinical trial for four indications i.e. chronic obstructive pulmonary disease, liver cirrhosis, osteoarthritis and diabetes mellitus. In Malaysia Stempeutics got NPCB approval for Cerebral Stroke and Osteo Arthritis phase I/II clinical trials. Stempeutics’ long-term objective is to market its products in the European and North American markets.


Manipal Education and Medical Group
 
 
 
Padma Bhusan
Dr. Ramdas Pai Chairman - Manipal Group		   Padma Bhusan
Dr. Y. K. Hamied
Chairman & MD - Cipla Ltd
 
 
 
News & Events
 
 
   Recognitions
 

  THE EMERGING COMPANY of the year 2011-12  
  Stempeutics bags the Emerging Company of the year for the two consecutive years - 2011 & 2012.  
     
     
  BioNexus status  
  Stempeutics is the first international company in Malaysia to receive the BioNexus status.  
     
     
  ICMR  
  Stempeutics, Bangalore, has been approved by Indian Council of Medical Research for Stem Cell Research activities  
     
     
  DSIR  
  Stempeutics Bangalore and Manipal R&D units have been recogonised by Department of Scientific and Industrial Research (DSIR)  
     
     
  NPCB  
  Stempeutics Malaysia gets NPCB (National Pharmaceutical Control Bureau, Malaysia) approval for Good Manufacturing Practices (GMP) in accordance to the current Pharmaceutical Inspection Co-operation Scheme (PIC/S) GMP Guides and its relevant Annexes for Isolation, Processing and Storage of Mesenchymal Stem Cell.         More...........  
     
   
 
Patents
Stempeutics strives towards building strong IP portfolio and is proactively engaged in extensive research in the area of stem cell technology and its application. To build a strong patent portfolio, we seek patent protection for our innovations at national and international levels.
  Corporate Social Responsibility: Manipal Foundation http://www.manipalfoundation.in  
 
 
   
  
Current Product:

Ex-Vivo cultured adult allogenic mesenchymal stem cells derived from donated bone marrow
 
Product Pipeline:
  Focus Areas   Status
  India    
  All clinical trials are approved by DCGI (Indian FDA)
  Osteo Arthritis (OA)   Clinical Trial Phase II
In progress
  Critical Limb Ischemia (CLI)

   Clinical Trial Phase II
In progress
  Liver Cirrhosis (LC)   Clinical Trial Phase II
In progress
  Chronic Obstructive Pulmonary Disease (COPD)

   Clinical Trial Phase II Approved
  Diabetes Mellitus(DM)   Clinical Trial Phase II Approved
  Acute Myocardial Infarction (AMI)   Clinical Trial Phase I Completed
  Malaysia    
  All clinical trials are approved by Malaysian FDA
  Osteoarthritis (OA)   Clinical Trial Phase II
In progress

  Cerebral Stroke (CS)   Clinical Trial Phase I/II Approved

       
 
Manipal Group: www.manipalgroup.com